POSITIVE IMPACTS INCLUDE REDUCED VIRAL LOAD AND HIGHER REMISSION RATES
PASADENA, Texas, January 12, 2022 / PRNewswire / – A clinical trial recently published in Gut Microbes – a leading journal reporting the latest scientific data on the microbiota – confirmed that Kaneka Group / AB-Biotics’ probiotic formulation AB21 shows significant positive effects in patients COVID-19 outpatient clinics. Based on the results of the study, the research group demonstrated that the probiotic formulation had a significant impact on many parameters measured from COVID-19 positive patients, including reduction in viral load, duration of symptoms and the remission rate.
The gut-lung axis (GLA) involves sophisticated cross-communication between intestinal and lung tissues via the microbiome and immune cells.I,I It is therefore speculated that probiotics may also benefit COVID-19 patients by influencing GLA.
The aim of the study was to study the impact of a probiotic formulation – composed of Lactiplantibacillus plantarum dyes (KABP022, KABP023 and KABP033) and Pediococcus acidilactici (KABP021) – in 293 COVID-19 outpatients with mild symptoms. The once daily supplement was administered for 30 days, and specific clinical parameters (including remission rate and duration of symptoms), nasopharyngeal and serum biomarkers, and the impact of the formula on the fecal microbiome were evaluated. After the intervention, complete remission was obtained by 53.1% of patients in the probiotic group and 28.1% in the placebo group. Probiotic supplementation also reduced nasopharyngeal viral load, pulmonary infiltrates, and the duration of digestive and non-digestive symptoms compared to the placebo group, and was well tolerated. No notable change in composition was detected in the fecal microbiota, but supplementation with probiotics significantly increased specific IgM and IgG antibodies against SARS-CoV2. This suggests that the probiotic formula influenced GLA primarily through the host’s immune system, rather than altering the makeup of the colonic microbiota. More research is needed to confirm the mechanism of action. It is important to note that the probiotic immune effects reported in the study cannot be extrapolated to other probiotic formulations, due to the specific strains used.
“The positive results reported by this study are an important step forward in our continued efforts to support COVID-19 patients”, comments MD Pedro Gutiérrez-Castrellón. “Few trials to date have found effective approaches to reduce symptom duration and viral load in COVID-19 outpatients. Hence, an oral probiotic that helps reduce viral load, lung infiltrates, and Duration of symptoms – like the AB21 probiotic intervention tested in this study – could help support COVID-19 outpatients more cost-effectively, and in addition to recognized standard therapies. ”
About AB-BIOTICS
BarcelonaAB-BIOTICS is a health sciences company that is part of the KANEKA group. AB-BIOTICS is focused on the research, development and distribution of clinically documented probiotic ingredients, which help improve the health and well-being of people.
About Kaneka
Kaneka Corporation, established in 1949, is a leading technology-driven enterprise, headquartered in Ossaka and Tokyo, Japan. Aligned with the overall business strategy, Kaneka focuses its activities on four strategic solutions units: materials, quality of life, healthcare and nutrition.
Kaneka is committed to promoting business development to provide solutions that support healthy and energetic living.
For press information, please contact: Camille Seoane, Barrett Dixon Bell, Craig Court, 25 Hale Road, Altrincham, Cheshire WA14 2EY, United Kingdom.
Tel: +44 (0) 161 925 4700. E-mail: [email protected]
i King S, Glanville J, Sanders ME, Fitzgerald A, Varley D. Effectiveness of probiotics on disease duration in healthy children and adults who develop common acute respiratory infectious diseases: a systematic review and meta- to analyse. Brother J Nutr 2014; 112: 41-54.
ii Hao Q, Dong BR, Wu T. Probiotics to prevent acute upper respiratory infections. Cochrane Database System. Rev. 2015; 2015: CD006895.
SOURCE Kaneka Americas Holding, Inc.
